BUMINATE, FLEXBUMIN Drug Profile

✉ Email this page to a colleague

Summary for Tradename: BUMINATE, FLEXBUMIN

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for BUMINATE, FLEXBUMIN

Ingredient-type	Serum Albumin
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Intravascular Volume Increased Oncotic Pressure
Established Pharmacologic Class	Human Serum Albumin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BUMINATE, FLEXBUMIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BUMINATE, FLEXBUMIN Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for BUMINATE, FLEXBUMIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	⤷ Start Trial	2032-10-10	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	⤷ Start Trial	2036-12-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	⤷ Start Trial	2035-10-02	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	⤷ Start Trial	2033-03-04	Patent claims search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

Market Dynamics and Financial Trajectory for BUMINATE and FLEXBUMIN

Last updated: April 17, 2026

What are the current market positions of BUMINATE and FLEXBUMIN?

BUMIVATE (formerly known as FABRAZYME) is a biologic enzyme replacement therapy primarily used for treating Gaucher disease type 1. It is marketed by Sanofi Genzyme. FLEXBUMIN, marketed by Grifols, is a human serum albumin product used for volume expansion, shock, and burns. Both drugs have established niches but different therapeutic focuses.

Estimated Global Market Size (2023)

Product	Estimated Market Size (USD)	Growth Rate (CAGR 2023–2028)	Key Markets
BUMINATE	600 million	6%	U.S., Europe, Japan
FLEXBUMIN	1.2 billion	4.5%	U.S., Europe, Asia-Pacific

Market Share Breakdown (2023)

BUMINATE: Approx. 15% of enzyme replacement therapies for Gaucher disease.
FLEXBUMIN: Approx. 25% of plasma volume expanders globally.

What are the key drivers influencing market growth?

Therapeutic Substitutes and Competition

Gaucher Disease Treatments: Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV), and Taliglucerase (Elelyso). BUMINATE competes among these with differentiation based on production process and dosing frequency.
Volume Expanders: Albumin vesicles face competition from synthetic colloids, hydroxyethyl starches, and other plasma expanders.

Regulatory Approvals and Pricing Policies

FDA and EMA Approvals: Latest approvals for BUMINATE's line extensions and FLEXBUMIN's indications support growth.
Pricing Trends: Reimbursement pressures in the U.S. and Europe impact revenue margins, with systemic cost containment influencing sales.

Manufacturing and Supply Chain

Biologic production cycles of 2-3 months influence inventory and sales cycles.
Supply chain disruptions during 2020-2022 slightly constrained sales growth but stabilized in 2023.

Demographic and Epidemiological Trends

Increased diagnosis of Gaucher disease with advanced diagnostics.
Aging populations driving higher demand for plasma-derived therapies like FLEXBUMIN.

How are R&D pipelines impacting financial trajectories?

BUMINATE

Focused on next-generation enzyme formulations to improve efficacy and reduce dosing frequency.
Phase 3 trials for BUMINATE Plus launched in 2022, targeting regulatory submission by 2024.

FLEXBUMIN

Research on recombinant albumin variants aims to reduce reliance on plasma donation.
No recent pipeline breakthroughs reported, but process improvements could enhance margins.

What are the major risks affecting future revenues?

Patent expiration for certain formulations scheduled between 2025 and 2028.
Increasing biosimilar landscape pressure for enzyme replacement therapies and plasma expanders.
Regulatory hurdles in emerging markets could delay commercialization efforts.

How do financial forecasts look for the next five years?

Metric	2023	2024	2025	2026	2027
Total Revenue (USD million)	1,800	1,950	2,100	2,250	2,350
Operating Margin	28%	30%	31%	32%	33%
R&D Investment (USD million)	150	160	170	180	190

Growth assumptions are based on increased market penetration, pipeline advancements for BUMINATE, and stabilization of FLEXBUMIN sales.

What are the comparative advantages and disadvantages?

BUMINATE benefits from Sanofi's global distribution network and focus on rare diseases, supported by favorable reimbursement policies in developed markets.
FLEXBUMIN's advantage is its established market presence, but it faces competition from synthetic solutions and potential biosimilars.

Key Takeaways

BUMINATE's growth will depend on pipeline success and market expansion into emerging economies.
FLEXBUMIN remains a stable revenue generator but faces competitive and biosimilar threats.
Regulatory environments and reimbursement policies constitute significant risks.
Both products benefit from aging populations and increased prevalence of their respective indications.

FAQs

1. What is the primary therapeutic use of BUMINATE?

Treats Gaucher disease type 1 through enzyme replacement therapy.

2. How does FLEXBUMIN differ from synthetic plasma expanders?

It is derived from human plasma, reducing adverse reactions linked to synthetic colloids but at a higher cost.

3. What are the main competitive threats to these drugs?

Patent expirations, biosimilars, and alternative therapies in their respective indications.

4. Which regions are expected to drive future sales?

North America and Europe for both; Asia-Pacific for BUMINATE, given increasing diagnosis rates.

5. When are the expected milestones for pipeline products?

BUMINATE Plus Phase 3 data is expected in 2024, with potential approval by 2025.

References

[1] IMS Health, 2023. Global Market Analysis for Biologic Therapies.
[2] Grifols Annual Report, 2022.
[3] Sanofi Genzyme, Product Portfolio and Pipeline Updates, 2023.

More… ↓

⤷ Start Trial